Published in J Urol on December 01, 2006
Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol (2015) 2.93
Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer (2008) 1.53
Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer (2010) 1.23
Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology (2009) 1.17
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology (2008) 1.15
A framework for assessment in oncology rehabilitation. Phys Ther (2009) 1.05
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male (2015) 0.97
Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv (2013) 0.96
Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl (2012) 0.95
Cardiac and cognitive effects of androgen deprivation therapy: are they real? Curr Oncol (2010) 0.95
Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology (2011) 0.93
Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl (2012) 0.92
Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis. BMC Cancer (2012) 0.92
Cognitive changes associated with ADT: a review of the literature. Asian J Androl (2012) 0.91
Hematological changes during androgen deprivation therapy. Asian J Androl (2012) 0.91
The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer (2013) 0.88
Differences in self-reported attentional fatigue between patients with breast and prostate cancer at the initiation of radiation therapy. Cancer Nurs (2011) 0.87
Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer (2009) 0.86
A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology (2009) 0.85
Exercise in clinical cancer care: a call to action and program development description. Curr Oncol (2012) 0.84
Age-related Differences in Symptoms and Their Interference with Quality of Life in 903 Cancer Patients Undergoing Radiation Therapy. J Geriatr Oncol (2011) 0.83
Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol (2008) 0.83
Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer. Prostate Cancer (2011) 0.79
Sleep and daily functioning during androgen deprivation therapy for prostate cancer. Eur J Cancer Care (Engl) (2010) 0.78
Effects of androgen deprivation on cerebral morphometry in prostate cancer patients--an exploratory study. PLoS One (2013) 0.78
The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nat Rev Urol (2016) 0.78
Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study. J Cancer Surviv (2016) 0.77
Quality of Life and Sexual Health in the Aging of PCa Survivors. Int J Endocrinol (2014) 0.77
Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training. J Aging Res (2011) 0.77
Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study. Urol Oncol (2012) 0.77
Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study. Soc Sci Med (2016) 0.76
Androgen Modulation of Hippocampal Structure and Function. Neuroscientist (2014) 0.76
No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study. Asian J Androl (2016) 0.76
Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer (2015) 0.75
Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study. Can Urol Assoc J (2017) 0.75
Clinical significance of androgen secretion disorders in men with a malignancy. Med Oncol (2017) 0.75
Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults. Am J Geriatr Psychiatry (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A greedy algorithm for aligning DNA sequences. J Comput Biol (2000) 47.89
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2001) 19.13
SAGEmap: a public gene expression resource. Genome Res (2000) 10.41
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer (1968) 4.88
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Laparoscopic ventral and incisional hernia repair in 407 patients. J Am Coll Surg (2000) 2.80
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res (1970) 2.47
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2000) 2.34
Causes of death of wild birds of the family Fringillidae in Britain. Vet Rec (1998) 2.26
Unconventional therapies for cancer: a refuge from the rules of evidence? CMAJ (1998) 2.24
Perception of quality of life by patients, partners and treating physicians. Qual Life Res (2000) 2.04
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
A radiation hybrid map of mouse genes. Nat Genet (2001) 2.03
Quality of cancer care. Ann Oncol (2004) 2.01
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
The proliferation of capillary endothelial cells. Cancer Res (1972) 1.81
High-glucose--triggered apoptosis in cultured endothelial cells. Diabetes (1995) 1.80
Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol (2001) 1.80
Bone metastases: pathophysiology and management policy. J Clin Oncol (1991) 1.70
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer (1980) 1.68
Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br J Radiol (1972) 1.67
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol (1988) 1.65
Politics, science, and the emergence of a new disease. The case of chronic fatigue syndrome. Am Psychol (1997) 1.63
Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol (2001) 1.57
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer (2006) 1.54
Ischemia in the ambulatory setting--the total ischemic burden: relation to exercise testing and investigative and therapeutic implications. J Am Coll Cardiol (1989) 1.54
The fate of abstracts submitted to a cancer meeting: factors which influence presentation and subsequent publication. Ann Oncol (1992) 1.54
Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab (2005) 1.51
APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry (2005) 1.49
Laparoscopic repair of traumatic diaphragmatic injuries. Surg Endosc (2002) 1.47
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer (2001) 1.47
French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. Support Care Cancer (2012) 1.45
Ototoxicity from ototopical aminoglycosides. J Otolaryngol (1997) 1.43
Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst (2012) 1.42
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol (2007) 1.42
Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood (2001) 1.39
Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst (1969) 1.39
v-Src and EJ Ras alleviate repression of c-Jun by a cell-specific inhibitor. Nature (1991) 1.35
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol (2001) 1.35
Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release (2001) 1.35
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer (1980) 1.33
The cell-type-specific activator region of c-Jun juxtaposes constitutive and negatively regulated domains. Genes Dev (1992) 1.32
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
Characterization of the mmsAB operon of Pseudomonas aeruginosa PAO encoding methylmalonate-semialdehyde dehydrogenase and 3-hydroxyisobutyrate dehydrogenase. J Biol Chem (1992) 1.31
Effect of whole-body vibration on BMD: a systematic review and meta-analysis. Osteoporos Int (2010) 1.29
Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology (2005) 1.28
Influence of vitamin A on immunological response. Immunology (1972) 1.28
Different brain networks mediate task performance in normal aging and AD: defining compensation. Neurology (2000) 1.28
Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol) (2007) 1.27
Isolation of different serovars of Salmonella enterica from wild birds in Great Britain between 1995 and 2003. Vet Rec (2006) 1.26
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol (1997) 1.25
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res (1999) 1.24
Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ (1998) 1.20
Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res (1986) 1.19
Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses (2001) 1.19
Uremic levels of BUN do not cause nitric oxide deficiency in rats with normal renal function. Am J Physiol Renal Physiol (2001) 1.17
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol (1998) 1.17
On the existence of a G 0 -phase in the cell cycle. Cell Tissue Kinet (1970) 1.17
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2014) 1.17
Controlled trial of clinical utility of serum salicylate monitoring in rheumatoid arthritis. J Rheumatol (1984) 1.15
Evaluation of the confidential unit exclusion form: the Canadian Blood Services experience. Vox Sang (2009) 1.12
High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol (1998) 1.12
An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol (2013) 1.11
Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol (2011) 1.11
Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.10
Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res (1989) 1.10
Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer (2006) 1.10
Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet (1988) 1.10
The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer (1998) 1.09
Vitamin A and the radiation response of experimental tumors: an immune-mediated effect. J Natl Cancer Inst (1972) 1.09
Laparoscopic-assisted panenteroscopy. Gastrointest Endosc (2001) 1.09
Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J Biol Chem (1995) 1.08
Sensitivity and specificity of free and total glutaric acid and 3-hydroxyglutaric acid measurements by stable-isotope dilution assays for the diagnosis of glutaric aciduria type I. J Inherit Metab Dis (1999) 1.08
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol (1994) 1.07
Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer (1993) 1.07
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol (2013) 1.06
Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use. Transfus Med (2009) 1.06
Induction of rapid histone degradation by the cytotoxic T lymphocyte protease Granzyme A. J Biol Chem (2000) 1.05
Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res (1983) 1.05
The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer (1996) 1.05
Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res (1992) 1.04
Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang (2012) 1.04
Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst (1990) 1.04
Distinct long-term neurocognitive outcomes after equipotent sevoflurane or isoflurane anaesthesia in immature rats. Br J Anaesth (2013) 1.04
Replication of genetic loci for ages at menarche and menopause in the multi-ethnic Population Architecture using Genomics and Epidemiology (PAGE) study. Hum Reprod (2013) 1.03
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1999) 1.03
Laparoscopic adrenalectomy for pheochromocytoma. Surg Endosc (2001) 1.03
Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res (1998) 1.02
Laparoscopic splenectomy in patients with normal-sized spleens versus splenomegaly: does size matter? Am Surg (2001) 1.02
Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant (2005) 1.01
Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex (2001) 1.01
Laparoscopic splenic cystectomy: a case report. J Pediatr Surg (1998) 1.00